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Abstract
Background: Acromegaly, an orphan disease usually caused by a benign pituitary tumour, is
characterised by hyper-secretion of growth hormone (GH) and insulin-like growth factor I (IGF-
1). It is associated with reduced life expectancy, cardiovascular problems, a variety of insidiously
progressing detrimental symptoms and metabolic malfunction. Treatments include surgery,
radiotherapy and pharmacotherapy. Pegvisomant (PEG) is a genetically engineered GH analogue
licensed as a third or fourth line option when other treatments have failed to normalise IGF-1
levels.
Methods: Evidence about effectiveness and cost-effectiveness of PEG was systematically reviewed.
Data were extracted from published studies and used for a narrative synthesis of evidence. A
decision analytical economic model was identified and modified to assess the cost-effectiveness of
PEG.
Results: One RCT and 17 non-randomised studies were reviewed for effectiveness. PEG
substantially reduced and rapidly normalised IGF-1 levels in the majority of patients, approximately
doubled GH levels, and improved some of the signs and symptoms of the disease. Tumour size was
unaffected at least in the short term. PEG had a generally safe adverse event profile but a few
patients were withdrawn from treatment because of raised liver enzymes. An economic model was
identified and adapted to estimate the lower limit for the cost-effectiveness of PEG treatment
versus standard care. Over a 20 year time horizon the incremental cost-effectiveness ratio was
£81,000/QALY and £212,000/LYG. To reduce this to £30K/QALY would require a reduction in
drug cost by about one third.
Conclusion: PEG is highly effective for improving patients' IGF-1 level. Signs and symptoms of
disease improve but evidence is lacking about long term effects on improved signs and symptoms
of disease, quality of life, patient compliance and safety. Economic evaluation indicated that if
current standards (UK) for determining cost-effectiveness of therapies were to be applied to PEG
it would be considered not to represent good value for money.
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Acromegaly is a rare endocrine disorder resulting from
excessive secretion of growth hormone (GH) [1,2]. The
underlying cause in more than 90% of patients is a benign
adenoma of the GH-secreting cells of the anterior pitui-
tary. Very rarely acromegaly is due to hypothalamic over
secretion of growth hormone releasing hormone (GHRH)
or to extra-pituitary tumours that secrete GH or GHRH.
GH promotes insulin-like growth factor-1 (IGF-1) secre-
tion. Prolonged exposure to elevated endogenous levels of
GH and/or IGF-1 in acromegaly results in excessive
somatic growth and metabolic dysfunction leading to
both direct and indirect tissue damage, secondary sys-
temic illness and reduced life expectancy. Extended dis-
cussion of the systemic complications can be found in
Colao et al 2004 [3], Melmed 2006 [1] and Chanson and
Salenave[2]
The insidious development of symptoms and their variety
contribute to delayed diagnosis of about 8 years from
onset of first symptoms [4]. Biochemical diagnosis is
made by immunoassay of GH and of IGF-1 in blood [1].
Traditionally excess secretion of GH has been targeted by
treatment strategies to reduce secretion; employing sur-
gery, radiotherapy, dopamine agonists (DOPAs), and/or
somatostatin agonists (SSAs) alone or as adjuvant to sur-
gery. Recently Pegvisomant (Somavert®; Pfizer) was devel-
oped with the aim of blocking the action of circulating
GH. Pegvisomant (PEG) is a genetically engineered ana-
logue of human GH that can compete with endogenous
GH for GH receptors while failing to activate the receptor.
As the effectiveness of PEG depends on competition with
GH the required dose is influenced by endogenous GH
levels which depend on the size, activity and type of ade-
noma. PEG is administered daily by subcutaneous injec-
tion. In Europe, PEG is licensed for patients who have had
an inadequate response to surgery and/or radiation and in
whom an appropriate medical treatment with somatosta-
tin analogues did not normalise IGF-1 concentrations or
was not tolerated[5].
Here we present a systematic review of the evidence about
the clinical effectiveness of PEG and an economic analysis
to estimate the cost-effectiveness of PEG treatment relative
to standard care.
Methods
The review was conducted according to a predefined pro-
tocol (available on request).
Search strategy clinical effectiveness
The following bibliographic databases and other sources
were searched for studies of clinical effectiveness: (i) Bib-
liographic databases: Cochrane Library (Wiley),
MEDLINE (Ovid), MEDLINE (Ovid) In-Process, EMBASE
(Ovid), CINAHL (EBSCO). (ii) Sources of information on
ongoing and unpublished research (including the
National Research Register and ClinicalTrials). (iii)
Sources of Abstracts and Proceedings (ZETOC, ENDO
2006 Endocrine Society's 88th annual meeting). (iv) Cita-
tions of relevant studies. (v) Experts in the field were con-
tacted to check that no published or unpublished studies
had been missed. (vi) Studies listed in systematic and
other reviews. The following bibliographic databases were
searched for economic studies: MEDLINE(Ovid);
EMBASE (Ovid); Cochrane Library (Wiley); NHS EED,
OHE HEED. Electronic databases were searched up to
March 2007. No language or date restrictions were
applied. Full details are in Additional File 1.
Inclusion and exclusion criteria for clinical studies
No systematic reviews were identified. Primary studies of
effectiveness were selected according the following crite-
ria: Study design: RCTs, quasi-randomised clinical trials,
comparative non-randomised studies, or case series if at
least 10 patients were included. Population: Patients diag-
nosed with acromegaly. Intervention: Treatment with PEG.
Comparator(s): any other or no treatment. Outcomes: Any
clinically relevant outcomes, changes in IGF-1 levels and
GH levels. Economic studies were selected using the fol-
lowing criteria: Study design: Cost-effectiveness, cost-utility
and cost-benefit studies. Health economic reviews were
also included. Population: People with acromegaly. Inter-
vention: PEG. Comparator: Any alternative treatment. Out-
comes: Quality of life, costs or incremental cost-
effectiveness ratio. Conference and symposium abstracts
were noted and used to check for studies published as full
papers.
The quality of included studies was assessed using stand-
ard check lists [6], and appropriate data were extracted
from included studies by one reviewer and checked by a
second. Application of inclusion criteria, quality assess-
ment and data extraction were undertaken by one
reviewer and checked by a second. Disagreements were
resolved by consensus.
Heterogeneity of clinical studies precluded meta-analysis
and clinical effectiveness was reviewed by narrative syn-
thesis. Studies that were multiply published were checked
and the most appropriate trial data extracted. Studies that
reported health-related quality of life (QoL) results for
patients with acromegaly but did not satisfy the inclusion
criteria were noted and if judged relevant were used to
inform the economic analysis.
Results
Number and type of studies identified
The electronic search yielded 319 citations (see Additional
File 2). After removal of duplicates and irrelevant citationsPage 2 of 15
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tions were obtained for further scrutiny. On application of
inclusion criteria 14 publications were excluded (see
Additional File 2 for reasons for exclusion). The main
characteristics of the eighteen included publications are
summarised in Additional File 3 (further details are pro-
vided in Additional File 4). The studies comprised one
multicentre RCT (Trainer 2000 [7]) of 112 patients ran-
domised to placebo or three different doses of PEG for 12
weeks; an open label extension of this RCT (Van der Lely
2001 [8]) with additional patients (total = 160) and
altered dose regimen; two publications describing analy-
ses of patient subgroups from the RCT [9,10]; a retrospec-
tive case series (n = 142) aimed at monitoring safety of
PEG treatment (Biering 2006 [11]); and 13 before versus
after PEG treatment comparisons [12-24], one of which
[12] was conducted retrospectively. Three of these publi-
cations (Paisley 2006; [13] Parkinson 2004 and Parkinson
2003 [14,15]) included a comparison with matched
healthy subjects in a cross sectional (i.e. single-time meas-
ure) design. In several instances the same patients were
involved in more than one of the above studies.
Populations recruited
PEG is licensed for patients with suboptimal response to
other treatments or who are intolerant of medical treat-
ment required to normalise GH and IGF-1 levels. The RCT
(Trainer 2000 [7]) was conducted prior to licensing. The
status of patients relative to the licensed indication is not
clear. One study, Colao 2006 [16], did recruit only
patients that had not satisfactorily responded to other
treatments.
Dose regimens and duration of treatment
In most studies a large loading dose (40 to 80 mg) of PEG
was administered on day one. After the loading dose in
the RCT doses of 10, 15 or 20 mg/day were given for 12
weeks. In most other studies, after loading, 10 mg/day was
administered but adjusted at timed intervals until serum
IGF-1 levels had declined to within normal range or a
maximum dose (e.g. 30 or 40 mg/day) was reached. The
dose regimen was halted, suspended or reduced if serum
liver enzymes rose to levels giving clinical concern. Three
studies [17-19] employed distinctly different dose regi-
mens from other studies. In Jehle 2005 [17] (n = 10), after
achieving IGF-1 normalisation, the interval between dos-
ing was first doubled (dose every other day) and then, if
IGF-1 normalisation was retained, doubled again. If, after
dose-frequency change, IGF-1 reverted to abnormal levels
then dose frequency was returned to the previously suc-
cessful frequency. In Jorgensen 2005 [19] (n = 11) PEG
was compared to PEG combined with long-acting SSA. In
Feenstra 2005 [18] PEG was administered weekly rather
than daily but was adjunct to monthly administration of
long-acting SSA treatment, and PEG dose was increased
until IGF-1 normalisation was achieved.
Follow-up of patients was short term in most studies.
Duration of study treatment period varied from as little as
12 weeks in many studies to 12 months in a few, or in the
more extended studies up to 2 years for a few patients
[8,9,17,20,21] (Additional File 3).
Outcomes reported
Signs and symptoms of disease were monitored in the
RCT and three other studies [7,16,17,21] using patient
questionnaires. Serum IGF-1 levels were almost univer-
sally reported. GH levels were reported in the RCT and its
extension [7,8] and a few small studies [9,16,19]. Several
studies focussed on risk factors for cardiovascular disease
[13,16,20,22], and/or for diabetes [17,19,20,23]. Two
studies focussed on markers of bone metabolism [10,15].
Side effects and transaminases levels were commonly, but
not universally, reported. None of the studies assessed
quality of life outcomes.
Risk of bias in included studies
Withdrawals from treatment in the RCT were fully
described and trial arms were balanced at baseline; the
publication provided few details of randomisation, allo-
cation concealment or blinding procedures. The greatest
risks for bias amongst the remaining studies (Table 1)
arose from a lack of clear information about the sampling
frame from which study participants had been selected
and a lack of description of the selection methods
employed. The rarity of acromegaly may have dictated the
use of convenience samples in most studies but this was
not explicitly reported.
Clinical effectiveness: signs and symptoms of acromegaly
The RCT [7] elicited patient information on signs and
symptoms using a questionnaire rating scale of 0 (no
symptoms) to 8 (severe, incapacitating) for each of five
symptom categories: soft tissue swelling, headache, joint
pain, excessive sweating, fatigue (Figure 1). At 12 weeks
statistically significant (p ≤ 0.05) improvements from
baseline were noted for the two high dose groups for soft
tissue swelling and excessive perspiration, and for all three
PEG groups for fatigue. No statistically significant changes
occurred for the placebo group except for fatigue which
worsened.
The small uncontrolled study of Jehle [17] (N = 10) noted
a trend for improvement over a mean treatment period of
15.3 (± 4.6) months. Colao [16] reported a favourable
trend toward improvement from baseline for 10 patients;
none of the changes in the individual symptom category
scores reached statistical significance. Schreiber [21]
reported statistically significant improvements (6 monthsPage 3 of 15
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Table 1: Assessment of risks to bias in non-randomised studies
Study Were 
eligibility 
criteria 
explicit?
Was 
sample 
source/
selection 
described?
Were 
patients 
assembled 
at same 
time?
Was a 
method 
of 
diagnosis 
stated?‡
Were 
clinical 
details 
described?
Was 
individual 
patient 
data 
reported?
Was 
outcome 
assessment 
blinded?
Was 
blinding 
method 
adequately 
described?
Was 
follow up 
time 
stated?Φ
Were 
withdraw
als 
stated?
Were 
reasons for 
withdrawal 
stated?
Barkan 
2005[24]
Y N CT N Y N N NA Y Y Y
Jorgensen 
2005[19]
Y Y CT N Y N N NA Y Y Y
Feenstra 
2005[18]
Y N CT N Y N N NA Y N NA
Van der 
Lely 
2001[8]
Y N N N Y N N NA Y Y Y
Sesmilo 
2002[9]
Y N CT Y Y N N NA Y Y Y
Fairfield 
2002[10]
N N CT N Y N N NA Y N NA
Parkinson 
2002[22]
N N CT N Y Y† N NA N N NA
Parkinson 
2003a[15]
Y N CT N Y N N NA N N NA
Parkinson 
2003b[23]
N N CT N Y Y† N NA Y N NA
Parkinson 
2004[14]
N N CT N N Y† N NA N N NA
Jehle 
2005[17]
N N CT N Y Y N NA Y Y Y
Paisley 
2006[13]
N N CT N Y Y N NA N N N
Biering 
2006[11]
CT Y NA N N Ya N NA N Y Y
Colao 
2006[16]
Y Y Y Y Y Y N NA Y Y Y
Pivonello 
2007[20]
Y N CT Y Y Y Y Y Y Y N
Schreiber 
2007[21]
N Y N N Y N N NA Y Y N‡‡
Parkinson 
2007[12]
Y N CT N Y Y Y N N N NA
a for subgroup of patients. ‡ in most studies this was implicit ("patients with established diagnosis") rather than explicit. † in graphs. Φ where patient follow up varied 
but group value only provided N is entered. ‡‡ for adverse events only.
Y = yes; N = no; CT = can't tell; NA = not applicable. Assessment used recommendations in the CRD handbook 2'edition [6]
BMC Endocrine Disorders 2009, 9:20 http://www.biomedcentral.com/1472-6823/9/20vs. baseline score) for soft tissue swelling, headache, joint
pain, general physical condition, and for total score. In
this study 62 patients (of 229) completed the question-
naire at baseline and 56 at 6 months into treatment. The
results may be susceptible to sampling bias. Both the RCT
and Jehle study reported statistically significant reduc-
tions in finger-ring size that were attributed to PEG ther-
apy.
Clinical effectiveness: tumour volume
In the RCT PEG treatment did not alter the group mean
tumour volumes relative to baseline and no individual
patient exhibited a clinically significant increase in
tumour volume [7]. In the RCT extension [8] (N = 131)
160 MRI image pairs were collected, one image at baseline
and another at an average of 11.5 months into treatment.
No statistically significant change from baseline was
observed in mean tumour volume. At baseline mean
tumour volume was 2.41 ml (95% CI: 1.8 to 3.0) and after
treatment was 2.37 ml (95% CI: 1.8 to 3.0). The mean of
individual change from baseline was - 0.033 ml (95% CI:
- 0.15 to + 0.08; p = 0.353 versus zero change). Two
patients had progressive tumour growth requiring treat-
ment, the authors could attribute no cause, and there was
no relationship between duration of treatment and
change in tumour size. Colao [16] reported a baseline
mean tumour size of 1.23 ml (95% CI: 0.55 to 1.91) for
14 patients; after treatment mean volume was 1.20 ml
(95% CI; 0.46 to 1.95); the mean change in volume was -
0.026 ml (95% CI; - 0.21 to + 1.56). Jehle [17] observed
small clinically insignificant increases in tumour size in 2
of 10 patients (duration of treatment 12 to 20 weeks).
Dual-therapy (PEG + SSA) studies [18,19] reported simi-
lar results (statistically non-significant).
Clinical effectiveness: achievement of normal IGF-1 levels
In the RCT [7] IGF-1 normalisation was the primary out-
come. Baseline IGF-1 levels were at least 1.3 times above
the top of the normal range. Statistically significant reduc-
tions in IGF-1 occurred after treatment in all three PEG
groups but not the placebo group (Figure 2); at all time
intervals after baseline statistically significant differences
Change in signs and symptoms of acromegaly reported in the RCTFigur 1
Change in signs and symptoms of acromegaly reported in the RCT. Mean and 95% confidence intervals of change at 
12 weeks relative to baseline. Raw data taken from Trainer 2000 [7].
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tinct dose response relationship was evident with higher
doses more effective than 10 mg PEG/day. At 12 weeks the
proportion of patients with normalised IGF-1 levels was
10%, 38%, 75% and 82% in placebo, 10 mg, 15 mg, and
20 mg PEG groups respectively. In the RCT extension [8]
PEG dose was titrated to achieve normal range IGF-1 with
a maximum allowed dose of 40 mg/day. Figure 2 shows
the reported IGF-1 levels. In the cohort treated for 12
months (n = 90) 97% had normalised IGF-1 levels.
Schreiber [21] collected IGF-1 data for 157 of 229 patients
at baseline and for 147, 102, and 39 patients after 6, 12
and 24 months (Figure 2). Mean group values were simi-
lar to those in the RCT extension [8]. At baseline 11% had
normal range IGF-1 and at 6, 12 and 24 months of treat-
ment 64%, 71%, and 76% were in normal range. These
percentages are distinctly lower than the 97% reported in
the RCT extension. Schreiber et al suggested this may be
due to better patient compliance and superior monitoring
for dose adjustment in a clinical trial compared to the real
world clinical practice reflected in their study. Colao [16]
reported individual IGF-1 levels for 16 patients that fitted
the licensed indication for PEG. Of 14 patients evaluated
at 12 months eight (57%) reduced IGF-1 to within nor-
mal range and three more to within 1 to 1.3 times normal
range.
Feenstra 2005 [18] and Jorgensen 2005 [19] combined
PEG with SSA therapy, whilst Jehle 2005 [17] attempted
reduction of dose frequency (Figure 2). Because daily PEG
is very expensive these strategies might reduce the overall
cost of maintaining IGF-1 within normal range. In Feen-
stra [18] at 18 weeks IGF-1 was normalised in 21/26
Decline in IGF-1 levels with PEG treatmentFigur 2
Decline in IGF-1 levels with PEG treatment. Baseline and follow up mean values with 95% confidence intervals reported 
in randomised [7] and non-randomised studies. The duration of treatment in the 5 phases of the Jorgensen study [19] was 2 to 
4 weeks, 8 weeks, 6 weeks, 6 weeks and 12 weeks. Dose of PEG in the RCT extension [8] and in Schreiber [21] varied accord-
ing to patient response. Figure compiled from published data [7,8,19,21] with the addition of 95% CI.
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ated); the median weekly PEG dose to achieve normalisa-
tion in those normalised was 60 mg/week. The Jorgensen
study [19] comprised 5 study phases: therapy with SSA,
withdrawal from SSA for 2 months, PEG at 10 mg/day (6
weeks), PEG at 15 mg/day (6 weeks), and finally 12 weeks
of 15 mg/day PEG combined with 30 mg long acting SSA
every 2 to 4 weeks. IGF-1 was measured at the end of each
study phase. The final combined therapy reduced IGF-1 to
lower levels than single therapy with either LASSA or PEG
but the difference just failed to reach statistical signifi-
cance. The lack of a true control for each phase of study
and problems of treatment carryover complicate interpre-
tation of these results. On combined therapy 9 of 10
patients achieved normal IGF-1 levels. Jehle 2005 [17]
investigated 10 patients who had failed to normalise IGF-
1 with DOPAs or SSAs. Mean PEG treatment was for 15.3
months; all patients normalised IGF-1 and 5 were able to
reduce frequency of dose administration to less than daily
while retaining a normal IGF-1.
Clinical effectiveness: effect on GH levels
In the RCT PEG treatment substantially increased serum
GH levels by up to 15 ng/ml above baseline levels (of ~8
ng/ml) and the increase from baseline reached statistical
significance for all three dose regimens. However, for
patients receiving placebo the change was small and not
statistically significant (Figure 3). A dose response rela-
tionship was evident with higher dose inducing greater
increase. In the RCT extension [8] for the cohort treated
for 6 months with PEG the mean GH level was substan-
tially elevated to double that at baseline (Figure 3).
Colao [16] reported individual GH levels for 16 patients.
The mean baseline GH ranged from 3.4 to 74.8ng/ml
(mean 23ng/ml; 95% CI: 10.9 to 35.0). After treatment,
discounting one patient who failed to inject PEG, the
range was 6.3 to 145ng/ml (mean 33.1; 95% CI: 11.3 to
54.9). Not all patients increased their GH level. The range
of change from baseline was -17 to + 52ng/ml and group
mean change from baseline was +10.8ng/ml (95% CI -1.7
to +23.3).
In the study of Jorgensen 2005 [19] (n = 11) PEG treat-
ment alone more than doubled group mean GH levels.
Subsequent combination of 15mg PEG/day with LASSA
treatment (every two to four weeks) appeared to decrease
GH levels and suppress some of the induced rise due to
PEG (difference in group means not statistically signifi-
cant). PEG may interfere with commercial kit-based
immunoassays for GH Paisley et al 2007 [25], and this
could impact on the quantitative interpretation of pub-
lished results.
Increase in GH levels with PEG treatmentFigure 3
Increase in GH levels with PEG treatment. Baseline 
and follow up mean values with 95% confidence intervals 
reported in randomised [7] and non-randomised studies. The 
duration of treatment in the 5 phases of the Jorgensen study 
[19] was 2 to 4 weeks, 8 weeks, 6 weeks, 6 weeks and 12 
weeks. Dose of PEG in the RCT extension [8] varied accord-
ing to patient response. Figure compiled from published data 
[7,8,19] with the addition of 95% CI.
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treatment
In the RCT [7] the 20mg/day PEG group experienced
slightly higher rates of adverse events than the placebo
group (Table 2). One patient withdrew from PEG because
of persistent headache and another due to raised serum
level of liver enzyme; one placebo patient also withdrew
for persistent headache. The RCT extension [8], and stud-
ies of Schreiber [21], and Jehle [17] also reported adverse
events (Table 2). The RCT extension [8] reported higher
rates of adverse events than the RCT. Of 160 participants
who received PEG thirty (19%) withdrew from treatment
for various reasons (nine for adverse events, five for lack
of efficacy, twelve "voluntarily", and two each were lost to
follow up or "violated protocol"). Overall withdrawal in
Schreiber [21] was unclear. In the 12 month study of
Colao [16] four of 16 patients (25%) withdrew or were
withdrawn, one each for: failure to inject PEG; raised liver
enzyme level; inability to follow the protocol; poor com-
pliance. The RCT extension [8] reported that liver enzyme
activities in serum remained within normal range during
PEG treatment. Schreiber [21] reported abnormally raised
serum levels of liver enzymes in 21 of 229 (9%) patients;
in 12 of these the levels were ≥ 3-fold above normal. Of
Table 2: Rate of adverse events reported in RCT and non-randomised studies
Adverse event Trainer 
2000[7]
Placebo
n = 32
Trainer 
2000[7]
PEG 10mg/d
n = 26
Trainer 
2000[7]
PEG 15mg/d
n = 26
Trainer 
2000[7]
PEG 20mg/d
n = 28
¶ †Open label
van der Lely 
(2001)[8]
PEG
n = 160
¶¶ ††Open 
label Scheiber 
(2007)[21]
PEG
n = 229
†††Open label 
Jehle 
(2005)[17]
PEG
n = 10
Infections 5* (16%) 5* (19%) 4* (15%) 5* (18%) 52 (33%) 1 (10%)
Headache 4 (12%) 3 (12%) 2 (8%) 3 (11%) 41 (26%) 4 (1.7%) 3 (30%)
Injection-site 
reaction
0 (0%) 2 (8%) 1 (4%) 3 (11%) 18 (11%) 17 (7.4%) --
Pain 2 (6%) 2 (8%) 1 (4%) 4 (14%) 36 (23%) -- --
Diarrhoea 1 (3%) 1 (4%) 0 (0%) 4 (14%) 23 (14%) -- --
Nausea 1 (3%) 0 (0%) 2 (8%) 4 (14%) -- -- --
Flatulence 0 (0%) 0 (0%) 1 (4%) 3 (11%) -- -- -v
Influenza-like 
syndrome
-- -- -- -- 33 (21%) -- --
Accidental injury -- -- -- -- 28 (18%) -- --
Hypercholesterol
emia
-- -- -- -- 23 (14%) -- --
Back pain -- -- -- -- 21 (13%) -- --
Asthenia -- -- -- -- 21 (13%) -- --
Arthralgia -- -- -- -- 19 (12%) -- --
Sinusitis -- -- -- -- 16 (10%) -- --
Insomnia 
(transient)
-- -- -- -- -- -- 2 (20%)
Fatigue -- -- -- -- -- -- 3 (30%)
¶Number of patients (%) with adverse events that occurred in at least 10% of patients.
¶P Number of patients (%) with adverse events occurring in > 1% and judged potentially causally related to PEG treatment.
† mean follow up 61 weeks. †† maximum follow up 102 weeks. ††† follow up 10 to 20 months. * upper respiratory tract infection only.Page 8 of 15
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normal during PEG treatment, levels returned to normal
in four patients after withdrawal of PEG and in one
patient level remained high but PEG was continued.
Details of six of Schreiber's patients were reported by Bier-
ing 2006 [11]. In this report 6 of 142 (4%) withdrew per-
manently from PEG because of raised liver enzyme levels.
Clinical effectiveness: miscellaneous outcome measures
A miscellany of further outcomes were reported mostly
from retrospective laboratory analyses of serum samples
for surrogate markers of disease-risk (diabetes, cardiovas-
cular disease, maladjusted bone turnover) in subgroups of
patients from other studies (mainly the RCT [7] and/or its
extension [8]). Four studies [9,13,16,22] reported on sta-
tistical significance of before versus after PEG treatment
changes in the levels of several risk markers for cardiovas-
cular disease. The findings (Table 3) were not consistent
between studies and no firm conclusions justifiable. One
study reported statistically significant improvement in
cardiac structure and function after 18 months of PEG
treatment using Doppler echocardiography[20].
Two studies [10,15] presented data on serum markers of
bone metabolism. The results (Table 4) support the prop-
osition that PEG reduces bone turnover in acromegaly;
how this translates to patient benefit requires further
investigation. Several small non-randomised studies
reported on laboratory measures relating to insulin and/
or glucose metabolism; these included those of Barkan
2005 (n = 53) [24], Parkinson 2002 (n = 20) [22], Parkin-
son 2003b (n = 16) [23], Colao 2006 (n = 16) [16], Jehle
2005 (n = 10) [17], Jorgensen 2005 (n = 11) [19]. The gen-
eral direction of findings was for a favourable change
indicative of improved metabolic adjustment. The signifi-
cance of these findings for patient well-being is difficult to
judge.
Economic analysis
One publication was included. This 2005 Technology
Assessment [26] for the Welsh Medicines Partnership
(WMP) described and critiqued a manufacturer's (Pfizer
UK Ltd) submitted decision analytic model of PEG treat-
ment versus standard care (SC) from the perspective of the
UK NHS. The WMP re-ran the model using "preferred
parameters". We were provided with a working version of
the manufacturer's model (MM). Figure 4 shows the deci-
sion tree structure of the model.
Description of Manufacturer's Model
The MM assumed SC to be treatment with long acting
SSAs. It considered 100,000 English male patients starting
treatment at an average age of 45 years and continuing
PEG for at least 20 years. Benefits of PEG derived from
improved survival and improved quality of life (QoL).
The survival of SC patients (the comparator population)
was obtained by applying a standardised mortality ratio
for acromegaly (2.63, Bates 1993 [27]) to the National
Statistics life table for English men aged 45 to 65 years. To
calculate survival benefit it was assumed that 92% of PEG
treated patients were responders and attained the survival
probability of English males while 8% were non-respond-
ers and remained in PEG treatment with the survival prob-
ability of standard care (SC) patients. For those who
stopped PEG treatment after 20 years survival probability
at each subsequent year thereafter was the same as that for
the SC survivors to that year. The resulting survival curves
are shown in Figure 4. The survival benefit was calculated
from the difference between survival curves. In the
absence of pertinent data a utility gain in QoL was
assumed to be equal to the disutility of patients experienc-
ing a coronary event (0.83 - 0.75 = 0.08) and in the MM
was experienced by all PEG treated patients (including the
8% non-responsive PEG-treated patients). The same gain
was applied for each year of PEG treatment. With dis-
counting at 3.5% for costs and benefits the MM delivered
incremental cost-effectiveness ratios (ICERs) at 20 years of
£105K/quality adjusted life year (QALY) and £194K/life
year gained (LYG).
Welsh Medicines Partnership's re-run of Manufacturer's 
Model
The WMP re-ran the MM using preferred parameters that
included survival of PEG responders taken as that of a mix
of Welsh men and women in proportion and with sur-
vival probability from National Statistics life tables; sur-
vival in SC was obtained by applying an SMR of 1.55
(Orme 1998 [28]). The impact of these changes on the dif-
ference in survival curves for PEG and SC treated individ-
uals is shown in Figure 4. The ICER generated at 20 years
was £748K/LYG.
Current author's re-run of Manufacturer's Model
We estimated a feasible lower limit for the ICER of PEG
treatment versus SC. To do this we adopted a "perfect
drug" scenario in which model inputs were all in favour of
PEG relative to SC but remained within reasonable
bounds set by available information. We assumed com-
plete compliance with PEG treatment and complete effec-
tiveness so that survival and QoL were returned to those
of the general population. This simplifies the model by
eliminating the non-responder arm (dashed line in Figure
4) as it was unrealistic that non-responder patients would
persist with PEG for 20 years. With regard to survival we
adopted two further changes: first the general population
was taken from National Statistics life tables for English
men and women aged 45 onwards; second we applied a
standardised mortality ratio of 3.6. We reasoned that sur-
vival of acromegaly patients eligible for PEG would likely
be poorer than for the generality of acromegaly patients,Page 9 of 15
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patients eligible for PEG to be more like that observed in
early studies before the development of long acting SSAs
which normalise IGF-1 and GH in many patients. In addi-
tion many of the patients eligible for PEG will have had
radiotherapy which is a known independent indicator of
poorer survival [29,30]. We therefore examined standard-
ised mortality ratios from studies of more than a decade
ago (Figure 5). We increased the highest ratio from these
studies by 10% giving a standardised mortality ratio for
the perfect drug scenario of 3.6. The resulting survival
curves are compared with the MM and WMP curves in Fig-
ure 4.
Table 3: Risk indicators for CVD: comparison for before v. after PEG There were small numbers of participants and changes for most 
markers did not reach statistical significance
Sesmilo 2002 [9]§
n = 26
Colao 2006 [16]
n = 16
Parkinson 2002 [22]†
n = 20
Parkinson 2002 [22]†
n = 20
Paisley 2006 [13]*
n = 20
PARAMETER Mean change from base-
line P
Paired t test
Before
v.
after Tx P
Paired t test Before
v.
after Tx P
Cases:
Before Tx
v.
after Tx P
Cases before Tx
v.
Healthy controls P
Total chol (mM) 0.22 NS NS Increased <0.01 Increased <0.01 0.16
HDL chol (mM) 0.006 NS Increased 0.0017 NS -- --
LDL chol (mM) -0.13 NS -- Increased <0.01 -- --
[Total/HDL] chol 0.21 NS Reduced 0.0012 -- -- --
TG (mM) 0.25 0.007 NS NS 0.3 0.13
Lipo (a) (mg/l) -70 0.039 -- Reduced <0.01 -- --
Apo B -- -- Increased <0.01 -- --
Apo A1 -- -- Increased <0.05 -- --
Homocysteine (?M) -0.16 NS -- -- -- --
CRP 2 0.0002 -- -- -- --
Interleucin 6 0.17 NS -- -- -- --
Blood pressure -- NS -- -- --
Fibrinogen -- NS -- -- --
Heart rate -- NS -- -- --
MMP-2 (ng/ml) -- -- -- Reduced <0.001 Higher <0.001
MMP-9 -- -- -- 0.76 0.87
VEGF -- -- -- Reduced 0.008 0.18
§ results for the open label part of the study, patients included if they normalised IGF-1 with treatment. It is unclear if the number of patients 
analysed was 34 or 26. † Units for Total chol and total TG given in paper as mM but are actually mg/dl. * It is possible that some participants may 
have been used in both these studies.
Apo A1 = apoprotein A1 (on HDL & chylomicrons). Apo B = apoprotein B (on LDL). chol = cholesterol CRP = C-reactive protein. HDL = high 
density lipoprotein. LDL = low density lipoprotein. Lipo (a) = lipoprotein little a. MMP = matrix metalloproteinase. NS = not statistically significant. 
P = probability. PEG = pegvisomant. TG = triacyl glyceride. Tx = treatment. VEGF = vascular endothelial growth factor.
Note: There were small numbers of participants and changes for most markers did not reach statistical significance.Page 10 of 15
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acromegaly patients relative to the general population; the
direction of evidence from these points to a negative rela-
tionship between QoL and IGF-1 levels, but no studies
have examined utility gain from PEG treatment. Rowles
2005 [31] reported utility values for QoL of acromegaly
patients (72.5% had active disease, 27.5% were in remis-
sion). Median utility was 0.7 (range -0.07 to 0.92) com-
pared to 0.81 for matched members of the general public.
To allow for the fact that patients eligible for PEG would
correspond to patients with active disease we approxi-
mated the utility of such patients as 0.66 (i.e. 0.81 -
([0.81-0.7] × [1/0.725])). The utility gain in the perfect
drug scenario was therefore 0.15 (i.e. 0.81 - 0.66) com-
pared to 0.08 in the MM.
The average dose of PEG/day for UK patients is 16.5 mg
(Pfizer UK Ltd, personal communication). At £100/20 mg
(BNF [37]) the average acquisition cost for PEG was taken
as £30,133pa (assuming vial splitting as necessary). Addi-
tional cost for MRI scans and laboratory tests (IGF-1 and
serum levels of liver enzymes) were £349pa (expert clini-
cal opinion and NHS reference costs [38]). For the perfect
drug scenario we assumed standard care patients were all
treated with long acting SSAs; this assumption favours
PEG since some patients are resistant to LASSAs and if
given pharmacotherapy would receive much cheaper
drugs (e.g. DOPAs). The MM used an annual acquisition
cost for long acting SSAs of £13,289; other independent
estimates range from £9,000 to £12,000 [39] and £7,000
to £14,000 [40]. We used £13,289pa. In addition, SC
included costs for scans and laboratory tests (£349pa as
above) and £1,771pa for treatments of co-morbidities
(Didoni 2004 [41]). The total annual cost for PEG and for
SC was £30,482 and £15,409 respectively.
At 20 and 40 years, with the inputs described above, the
perfect drug scenario delivers ICERs of £81K/QALY and
£212/LYG and £65K/QALY and £94K/LYG respectively.
To reduce the ICER at 20 years to £30K/QALY would
require a reduction in PEG cost by about one third.
Discussion
With regard to the volume and quality of evidence on the
effectiveness of PEG, difficulties in patient recruitment
may partly explain the existence of only a single RCT, and
the participation of overlapping populations of patients
amongst multiple studies. Most non-randomised evi-
dence came from "convenience" samples and these stud-
ies were susceptible to biases of patient selection and in
Table 4: Indicators of bone formation and soft tissue turnover
MARKER Parkinson 2003 
[15]Φ baseline
Parkinson 
2003[15]Φ At IGF-1 
normalisation
P v. baseline Fairfield 
2002[10]ΦΦ 
placebo 12 wks
Fairfield 
2002[10]ΦΦPEG 
12 wks
P v. placebo
Bone formation
osteocalcin 47θ (14 - 109) 21 (10 - 73) < 0.001 +0.01θθ (0.39) -2.2 (0.44) 0.009
terminal propeptide 
procollagen I
70θ (12) 38 (8) < 0.01 +18.1θ (12.8) -23.6 (9.6) 0.022
bone alkaline 
phosphatase
147θθθ (29) 120 (23) < 0.05
Bone resorption
cross linked 
telopeptide of 
collagen I
0.8Ψ (0.2 - 2.4) 0.4 (.03 - 1.3) <0.0001 +1θθ (0.3) -4.4 (1.4) 0.024
urinary ratio cross 
linked telopeptide/
creatinine
92θθθ 56 (14) < 0.01
Soft tissue 
formation
terminal propeptide 
of procollagen III
4.3θ (0.3) 3.1 (0.3) <0.01
Φ data are mean (SEM) or median (range); ΦΦ data are mean (SEM); θ ug/L; θθ nmol/L; θθθ units unclear. Ψ pmol/L.Page 11 of 15
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was small and follow up was short with relatively little or
unclear reporting about withdrawals from treatment. It is
likely very few studies investigated the "licensed popula-
tion". The RCT was conducted before licensing. In 2006
Colao [16] commented "all these studies were not designed
to investigate the response to pegvisomant in patients with
proven resistance to long-term, high dose therapy with somato-
statin analogues; these are the patients allowed to receive pegvi-
somant treatment in Europe according to the product label."
Convincing evidence indicated that adequate dosage of
PEG delivers significant reductions in IGF-1 levels and a
substantial proportion of such patients are brought within
normal range [7,8,16,18,21]. In contrast the levels of GH
appear on average to be considerably increased by PEG
treatment as shown in the twelve week RCT [7], the
uncontrolled extension [8] and by two small non-ran-
domised studies [16,19]. Individual patient data shows
GH may not increase in all patients [16]. Tumour size is
apparently unaffected by PEG treatment [8,16-19,21,24],
at least in the short term, however continued vigilant
monitoring of tumour size is mandatory during PEG treat-
ment.
In the twelve week RCT [7] PEG improved patient scores
for five signs and symptoms of disease (soft tissue swell-
ing, arthralgia, headache, excessive perspiration and
fatigue). The improvements reached statistical signifi-
cance for tissue swelling, perspiration and fatigue. Several
Model structure and survival curvesFigure 4
Model structure and survival curves. Manufacturer's (MM), Welsh Medicines Partnership (WMP) and perfect drug sce-
nario (PD) input survival curves used in economic model. Data input shown as symbols, solid lines represent Gompertz distri-
butions fit to data. In the MM and WMP models PEG treatment continues for 20 years and compliance is 92%. GP = general 
population (survival in PEG-compliant patients returns survival to that of the general population). SC = standard care (survival 
in standard care derived by applying a standardised mortality rate (SMR = 2.63 for MM, 1.5 for WMP, and 3.6 for PD) to the 
survival of the GP). The curves shown are modelled using mortality data from the Office of National Statistics for England 
(population about 50 million) or for Wales (population about 5 million) as appropriate.
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improvement.
Increased mortality in acromegaly has been associated
with cardiovascular problems. The effect of PEG upon risk
indicators for cardiovascular disease was examined in sev-
eral of the non-randomised studies included in this review
but the results were not wholly consistent or easily inter-
preted. A single small 18 month non-randomised study
[20] provided evidence that PEG induces favourable
changes in cardiac structure and performance.
The limited available information indicates that PEG has
a generally mild adverse event profile but occasionally
raises liver enzyme levels necessitating temporary or very
occasionally permanent withdrawal [16,21]. This means
monitoring for possible liver damage is a necessity during
long term administration of PEG. Other side effects
include headache, injection-site reactions, flu-like syn-
drome and recently injection-site lipodystrophy sufficient
to cause discontinuation has been reported [42]. Antibod-
ies to PEG appear rarely to have been measured. Evidence
is lacking about any relationship between anti-GH anti-
bodies and decrease in efficacy or an increase in adverse
events frequency.
The economic model with input parameters all favouring
PEG relative to standard care (a perfect drug scenario)
showed that over a 20 year time horizon the cost effective-
ness of PEG is very unlikely to fall below £80,000/QALY
or £212,000/LYG. In the absence of special criteria for the
assessment of orphan drugs, this means that PEG is
unlikely to represent good value for money when consid-
ered against the current standards applied to interventions
in the UK Health service.
Conclusion
PEG effectively reduces IGF-1 levels and improves signs
and symptoms of acromegaly. Adverse events associated
with treatment are of relatively minor severity and low
prevalence, at least in the short term, and compliance is
probably about 80%. When considered against the norms
currently used to determine cost-effectiveness within the
UK, PEG does not represent good value for money. For
PEG treatment to be more acceptable to commissioners
special criteria appropriate to orphan drugs would need to
be adopted or the cost of PEG reduced.
SMR values reported in acromegaly studiesFigure 5
SMR values reported in acromegaly studies. Standardised mortality ratios reported in studies of patients with acromeg-
aly, sorted according publication in last decade or earlier.
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